Arthur M. Cohen & Associates, LLC Denali Therapeutics Inc. Transaction History

Arthur M. Cohen & Associates, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 10, 2024	SELL	$16.2 - $23.18 $38,507 - $55,098	-2,377 Reduced 18.37%	10,564 $226,000
Q3 2023 Oct 20, 2023	SELL	$20.63 - $30.17 $168,939 - $247,062	-8,189 Reduced 38.76%	12,941 $266,000
Q2 2023 Jul 19, 2023	BUY	$23.37 - $32.96 $85,323 - $120,336	3,651 Added 20.89%	21,130 $623,000
Q1 2023 Apr 24, 2023	BUY	$21.91 - $32.67 $46,909 - $69,946	2,141 Added 13.96%	17,479 $402,000
Q3 2022 Oct 21, 2022	BUY	$25.97 - $38.53 $75,884 - $112,584	2,922 Added 23.53%	15,338 $471,000
Q4 2021 Jan 24, 2022	BUY	$42.59 - $55.02 $207,370 - $267,892	4,869 Added 64.52%	12,416 $554,000
Q3 2021 Oct 08, 2021	BUY	$48.48 - $78.23 $200,658 - $323,793	4,139 Added 121.45%	7,547 $381,000
Q2 2021 Jul 27, 2021	BUY	$50.3 - $78.44 $171,422 - $267,323	3,408 New	3,408 $267,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Arthur M. Cohen & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Arthur M. Cohen & Associates, LLC with notifications on news.